. Author manuscript; available in PMC: 2012 Jul 15.

Published in final edited form as: Pediatr Blood Cancer. 2011 Feb 15;57(1):126–134. doi: 10.1002/pbc.23025

Table V.

Platinum Compound Dose and Relative Risk of Late Auditory Conditions > 5 Years Post-Diagnosis

		Platinum Dose Relative Risk^* (95% CI)
Auditory Condition	Radiation strata	1–349mg/m2	350+mg/m2
Problems hearing sounds		2.1 (1.1–4.1) ^a	1.9 (1.0–3.5) ^a
Tinnitus		3.8 (2.2–6.8) ^b	2.1 (1.1–4.2) ^a
Hearing loss	50+ Gy	1.4 (0.3–5.7)	1.5 (0.5–4.7)
	< 50 Gy	4.2 (1.3–14) ^a	11.0 (5.2.–23.2) ^b
Deafness	50+ Gy	---	0.5 (0.1–3.6)
	< 50 Gy	2.7 (0.6–11.8	5.4 (1.6–18.2) ^b

Relative risks for doses shown vs no platinum. Models adjusted for age at diagnosis, gender, and maximum radiation dose to posterior fossa or temporal lobe and VP shunt placement;

---: not estimable;

p value <0.05;

p value <0.01